Abstract:Background. The prognosis of patients with multiple myeloma (MM) is significantly different depending on the biological characteristics of the tumor substrate, the microenvironment of the bone marrow, as well as factors associated with the patient’s body. Therefore, the search for new reliable and easily identifiable prognostic markers is relevant for the effective management of patients with this disease. The objective of the study was to assess the prognostic value of the study of serum free light chains (FLC) of immunoglobulins κ and λ and their ratio κ / λ FLC in the blood serum of patients with newly diagnosed MM in real clinical practice. Materials and methods. 369 patients with first diagnosed MM (134 men and 235 women) were examined who were hospitalized in the hematology department of the City Clinical Hospital No. 2 Novosibirsk in the period since January 2012 to December 2017. The median age of the patients was 67 (32–82) years. All patients received induction courses of chemotherapy based on bortezomib. The control group consisted of 56 conditionally healthy individuals: 34 women (60.7 %) and 22 (39.3 %) men with a median age of 62 (40–68) years. The concentration of FLC-κ and FLC-λ (mg / L) in blood serum was determined by immunoturbidimetric method on a Hitachi 911 automated biochemical analyzer using the Freelite Human Lambda and Freelite Human Kappa reagent kits (Binding Site, Great Britain). Results. It was found that in patients with MM, the concentration of serum FLC-κ or FLC-λ was statistically significantly higher compared to the control group and varied depending on the type of MM (p <0.001). The diagnostic sensitivity of the quantitative determination of FLC and their ratio for MM was 98.64 %, compared with 94.04 % in a standard immunochemical study. The values of the ratio κ / λ FLC 65, as well as the concentration of FLC-κ and FLC-λ are higher than the median obtained in the whole group (FLC-κ ≥702 mg / L and FLC-λ ≥493.2 mg / L), correlate with known factors of poor prognosis for MM (with a high concentration of β2‐microglobulin (>3.5 mg / L) (r = 0.461; p 60 % (r = 0.420; p 177 μmol / L) (r = 0.380; p = 0.002), and also with high lactate dehydrogenase activity (>450 U / L) (r = 0.520; p <0.001) and is associated with poor outcomes. The median overall survival in the group of patients with κ / λ FLC 65 was 49 months compared to 76 months in the group with κ / λ FLC 0.04–65 (log-rank p = 0.012). Conclusion. The determination of free FLC in the blood serum of patients with MM can be used to assess the prognosis of their survival. The value of the κ / λ FLC ratio 65 allows us to divide patients with MM into risk groups with significantly different outcomes and can be used to identify patients at high risk who need more aggressive therapy and more detailed monitoring of the response.

Diagnostic significance and application value of serum free light chain detection in kidney related diseases

[Detection of Serum Free Light Chain and Its Clinical Significance in Nonsecretory Multiple Myeloma].

Application of serum free light chain and kidney-related small molecule metabolite in early diagnosis of multiple myeloma complicated with renal injury

Clinical significance of serum free light chain in patients with multiple myeloma]

The clinical value of serum free light chain measurement in multiple myeloma

[Clinical Significance of Serum Free Light Chain in Monoclonal Gammopathy].

Value of Serum Free Light Chain in Differential Diagnosis of Hypergammaglobulinemia

[The Clinical Significance of Serum Free Light Chain in Primary Systemic Amyloidosis].

Clinical Significance of Serum Free Light Chain Test in the First Onset of Multiple Myeloma

The Significance of Serum Light Chain Ratio in the Diagnosis of Multiple Myeloma and Primary Nephritic

Establishment of medical reference ranges of serum free light chain ratio in Shanghai population and its diagnostic value on PCN

Expression and diagnostic value of serum free light chain in lung cancer

[The Diagnostic and Prognostic Values of Serum Free Light Chain in Patients with Primary Light Chain Amyloidosis].

The response assessment value of serum free light chain in the chemotherapy for IgG multiple myeloma

The clinical application of serum κ/λ light chain ratio and protein electrophoresis in the diagnosis of multiple myeloma

Judging disease activity in rheumatoid arthritis by serum free kappa and lambda light chain levels.

Clinical Significance of Abnormal Serum Free Light Chain Ratio: Diagnostic Confusion or Underlying Monoclonality?

The importance of serum immunoglobulin free light chain assessment for predicting outcome in patients with newly diagnosed multiple myeloma in real clinical practice

Free Light Chain Levels in Pediatric Patients with Inflammatory Conditions.

Value of urine α1 microglobumin and β2 microglobumin for the diagnosis of stage 2 -4 chronic kidney disease

Application value of routine biochemical tests in patients with preliminary diagnosis of multiple myeloma